Clinical Trial · NCT06494800

Added Value of 18F-FDG PET/CT in Lung Cancer

Overview

Assess the value of PET/CT in the diagnosis, staging, response evaluation, and relapse monitoring of lung cancer.

Phase

N/A

ClinicalTrials.gov

NCT06494800

Drug / Compound

Isotope(s):
Target(s):